Addex Therapeutics (FRA:APE1) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 27, 2026)


FRA:APE1 Addex Therapeutics Ltd FRA:APE1
7 GF Score
Price €4.90
GF Value €1.12
! 6 Warning Signs
View Full Analysis

What is Addex Therapeutics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Addex Therapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:APE1 vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Addex Therapeutics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Addex Therapeutics Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Addex Therapeutics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Addex Therapeutics's Margin of Safety % (DCF Earnings Based) falls into.


FRA:APE1
7GF Score
Addex Therapeutics Ltd FRA:APE1
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Addex Therapeutics (FRA:APE1) Overvalued in 2026?

Based on GuruFocus' analysis, Addex Therapeutics stock appears to be overvalued. The current stock price of €4.90 is trading 337.5% above its estimated GF Value™ of €1.12.

Key valuation signals for FRA:APE1:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €1.12 vs. price of €4.90 (337.5% above fair value)
  • GF Score™: 7/100 with 6 warning signs

No single metric tells the full story. See the FRA:APE1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Addex Therapeutics Business Description

Address Chemin des Mines 9, Geneva, CHE, 1202
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
7GF Score

Get the complete analysis for FRA:APE1

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.90
Price
€1.12
GF Value